Cargando…
T36. THE ANTIPSYCHOTIC-LIKE PROPERTIES OF EVENAMIDE (NW-3509) REFLECT THE MODULATION OF GLUTAMATERGIC DYSREGULATION
BACKGROUND: The lack of adequate benefit with current 5HT2 / D2 antipsychotics in large proportions of schizophrenic patients suggests it is essential to modulate other mechanisms for improving symptoms of schizophrenia (SCZ). Increasing evidence implicates NMDAr hypofunction, and hippocampal hypera...
Autores principales: | Bortolato, Marco, Faravelli, Laura, Anand, Ravi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888763/ http://dx.doi.org/10.1093/schbul/sby016.312 |
Ejemplares similares
-
T48. ANTIPSYCHOTIC EFFICACY OF EVENAMIDE (NW-3509) IS DUE TO MODULATION OF GLUTAMATERGIC DYSREGULATION
por: Anand, Ravi, et al.
Publicado: (2018) -
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
por: Anand, Ravi, et al.
Publicado: (2023) -
Evenamide, as an add-on to antipsychotics, benefits patients with treatment resistant schizophrenia: 6-month interim results from the first 100 patients in an ongoing international randomized study
por: Anand, R., et al.
Publicado: (2023) -
Mintaimycins, a Group of Novel Peptide Metabolites from Micromonospora sp. C-3509
por: Hu, Xiaomin, et al.
Publicado: (2022) -
3509 Developing a Leadership Alumni Forum to foster a culture of leadership at Mount Sinai
por: Gabrilove, Janice Lynn, et al.
Publicado: (2019)